1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zhejiang Starry Pharmaceutical Co.,Ltd.

Zhejiang Starry Pharmaceutical Co.,Ltd.

603520.SS
Zhejiang Starry Pharmaceutical Co.,Ltd.CN flagShanghai Stock Exchange
9.35
CNY
-0.32
- -
4.10BMarket Cap
Zhejiang Starry Pharmaceutical Co.,Ltd.
603520.SS
(Shanghai Stock Exchange)

Recent

price

9.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.05
2.34
2.79
2.66
2.83
2.19
2.15
2.72
3.95
4.09
5.81
6.18
6.45
5.74
4.78
5.06
Revenue per Share
0.27
0.15
0.26
0.27
0.28
0.25
0.25
0.29
0.51
0.71
0.94
-0.22
0.13
-0.12
0.02
-0.09
Basic EPS, GAAP
-0.69
-0.14
-0.46
-0.25
-0.61
-0.59
-0.18
0.09
0.34
0.06
0.6
-1.6
-0.65
-0.7
-0.52
-0.96
Free Cash Flow per Basic Share
0.06
0.09
0.17
0.26
0.37
0.28
0.27
0.33
0.36
0.45
0.58
0.63
0.58
0.31
0.29
0.35
Dividend per Share
0.54
0.67
0.85
0.97
1.03
1.02
1.05
1.12
1.61
2.31
2.71
2.4
2.35
2.02
1.5
1.7
Book Value per Share
1.08
1.11
1.18
1.32
1.44
2.36
2.31
0.57
0.93
3.4
4.21
3.01
3.05
4.71
3.65
4.04
Tangible Book Value per Share
247
245
246
248
246
307
331
328
331
334
344
345
340
409
511
478
Basic Weighted Avg Shares
507
575
686
658
696
673
711
890
1,309
1,367
2,000
2,131
2,196
2,350
2,446
2,418
Sales/Revenue/Turnover
18.06
11.03
14.26
16.45
19.2
17.17
18.19
20.79
26.45
26.72
24.01
8.07
8.05
4.09
5.6
3.3
Operating Margin (%)
24
36
44
51
58
65
72
85
109
126
155
160
180
222
241
- -
Depreciation Expense
68
36
64
68
69
76
83
94
170
239
324
-76
44
-49
10
-43
Net Income, GAAP
13.02
16.1
14.91
16.06
21.32
22.11
21.32
19.52
17.57
16.5
16.6
- -
1.76
- -
- -
45.67
Effective Tax Rate (%)
13.34
6.23
9.28
10.28
9.91
11.31
11.69
10.52
13.01
17.46
16.19
-3.56
2.01
-2.09
0.42
-1.77
Profit Margin (%)
37
-69
-113
-99
-134
55
152
-294
-363
406
176
-588
-667
-447
-166
-250
Working Capital
85
49
110
227
354
387
490
866
842
995
747
675
734
537
946
812
LT Debt
302
337
386
432
458
827
872
923
1,029
1,865
2,215
1,771
1,759
2,634
2,564
2,633
Total Equity
- -
8.21
10.46
9.54
8.96
5.82
5.57
6.38
9.69
8.6
9.88
- -
3.72
- -
- -
- -
Return on Invested Capital (%)
- -
12.01
14.25
12.43
9.5
7.96
8.47
7.93
9.23
10.85
13.12
- -
3.87
- -
- -
7.05
Return on Capital (%)
- -
24.03
34.13
30.11
27.84
26.86
25.19
26.27
37.87
36.59
37.95
-8.61
5.44
-6.04
1.29
-4.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,027
1,988
1,807
LT Borrowings
537
628
812
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
438
438
438
Market Capitalization
2,668
4,021
4,686

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,231
2,306
2,059
Cash, Cash Equivalents & STI
603
411
433
Accounts Receivable, Net
305
453
554
Inventories
1,105
1,088
951
Total Current Liabilities
2,677
2,768
2,309
Payables & Accruals
- -
- -
- -
ST Debt
2,027
1,988
1,807
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.98%
9.03%
-2.67%
Free Cash Flow
46.26%
91.06%
-7.52%
Net Income, GAAP
-42.37%
-115.59%
-120.83%
Sales/Revenue/Turnover
14.6%
13.4%
4.07%
Total Cash Common Dividend
6.85%
2.47%
13.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
642
688
474
546
2,350
2025
686
712
601
- -
2,446
2026
711
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
-0.12
2025
0.03
- -
- -
- -
0.02
2026
0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
- -
- -
- -
0.31
2025
0.04
- -
- -
- -
0.29
2026
0.04
- -
- -
- -
- -
Similar Companies
Torii Pharmaceutical Co., Ltd. (TRXPF)
Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
Elixinol Wellness Limited (ELLXF)
Guangdong Lifestrong Pharmacy Co., Ltd. (301111.SZ)
Hansoh Pharmaceutical Group Company Limited (3692.HK)
The Flowr Corporation (FLWPF)
Business
Zhejiang Starry Pharmaceutical Co., Ltd. (603520.SS) develops, manufactures and sells active pharmaceutical ingredients and finished dosage forms focused on X-CT non-ionic contrast agents and fluoroquinolones series; its API products include iohexol, iohexol hydrolysate, ioversol, iopamidol, iomeprol, iopromide, iodixanol, gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, levofloxacin, levofloxacin hydrochloride, levoflurane, pazufloxacin and pazufloxacin mesylate; finished dosage forms cover full concentrations of iodine contrast agents such as ioversol injection. The company operates production bases and subsidiaries in China, including Jiangxi Starry Pharmaceutical Co., Ltd., Shanghai Starry Pharmaceutical Co., Ltd., Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. and Shanghai Jianhe Pharmaceutical Technology Co., Ltd., with international presence through Imax Diagnostic Imaging Limited in Ireland; it supplies CMO and CDMO services to global markets, holding registrations in China, the EU, Japan, India, South Korea and U.S. FDA DMF approval. Founded in 1997 and headquartered in Xianju, Zhejiang Province, China, the company listed on the Shanghai Stock Exchange in 2016 and pursues import substitution in contrast agents with leading domestic iohexol API capacity. Recent developments include commercial FDF production since 2020, winning national centralized procurement bids in 2021 and 2022 to supply over 3,000 hospitals across nearly 30 provinces; Shanghai Starry's ioversol injection approval in October 2023; Jiangxi Starry's gadobenate dimeglumine API approval in February 2024; and a May 2024 issuance of 95.9 million A shares to bolster capital. In October 2024, Ni Lianhui acquired a 5.02% stake from existing shareholders, marking a notable ownership change.